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Abstract Histologic grade is a significant predictor of
outcome in salivary gland carcinomas. However, the sheer
variety of tumor type and the rarity of these tumors pose
challenges to devising highly predictive grading schemes.
As our knowledge base has evolved, it is clear that carci-
noma ex pleomorphic adenoma is not automatically a high
grade tumor as is traditionally suggested. These tumors
should be further qualified as to type/grade of carcinoma
and extent, since intracapsular and minimally invasive
carcinomas ex pleomorphic adenoma behave favorably.
The two carcinoma types for which grading schemes are
common include adenoid cystic carcinoma and mucoepi-
dermoid carcinoma. Adenoid cystic carcinomas are graded
based solely on pattern with solid components portending a
worse prognosis. Occasionally, adenoid cystic carcinomas
may undergo transformation to pleomorphic high grade
carcinomas. This feature confers a high propensity for
lymph node metastasis and should thus be reported to alert
the clinical team. Mucoepidermoid carcinomas are graded
in a three tier fashion based on a constellation of features
including cystic component, border, mitoses, anaplasia,
and perineural invasion among others. All grading schemes
are somewhat cumbersome, intimidating and occasionally
ambiguous, but evidence suggests that using a scheme
consistently shows greater reproducibility than using an
intuitive approach. The intermediate grade category dem-
onstrates the most variability between grading systems and
thus the most controversy in management. In the AFIP
system intermediate grade tumors cluster with high grade
tumors, while in the Brandwein system, they cluster with
low grade tumors.
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Introduction
Salivary gland carcinomas comprise only 3–5% of all head
and neck malignancies, yet they are the most diverse with
at least 24 different types recognized by the World Health
Organization (WHO) [1]. This diversity combined with the
rarity of many of the tumor types and the unpredictability
in long-term outcome impose a significant challenge on the
management of salivary gland malignancies overall [2].
For prognosis and treatment, despite these aforementioned
factors, it is critical to resolve these tumors, using both
clinical and pathologic parameters, into therapeutically
meaningful categories (Table 1) [3].
A review of numerous retrospective studies [4] indicates
that histologic tumor grade ranks highly among the most
important predictors of outcome for salivary gland carci-
nomas. High grade salivary carcinomas have a 5 year
survival of roughly 40% while low and intermediate grade
tumors have a 5 year survival of 85–90% [2, 4]. In sizeable
series, histologic grade is an independent predictor of
outcome in multivariate analysis, but it also tends to cor-
relate with other adverse prognosticators such as size and
nodal status. However, the current approach to grading of
salivary gland tumors is subject to many deficiencies and
challenges that on a case by case basis may not always
accurately predict outcome. Here I review current
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histologic grading as applied to salivary gland carcinomas
in general and with respect to select common tumor types.
Discussion
General Grading of Salivary Gland Carcinomas
The ideal requirements for any grading system are as
follows:
• Accurately predicts outcome
• Can be used to stratify patients into distinct manage-
ment categories
• Applicable to all sites in which a tumor can be seen
• Simple criteria
• Quick and time efficient
• Reproducible with minimal inter and intraobserver
variability.
Practically speaking, this ideal is difficult or even
impossible to achieve in salivary gland carcinomas mainly
because of the lack of sufficient sample size to devise
statistically valid systems that fulfill the aforementioned
criteria. Meta analyses hold very little meaning since
grading of salivary gland carcinomas is not standardized.
Most grading is done ‘intuitively’ using general cytomor-
phologic features (pleomorphism, mitoses, necrosis) and is
thus highly individualized. Even when grading systems
exist, there may be several to address the same tumor type,
none of which correlate exactly with one another.
Despite these obstacles, using the data available, as well
as good clinical acumen, the various tumor types can at
least be stratified into a meaningful working stratification
scheme that can be used to parse tumors into those that do
not require treatment beyond excision (i.e. low risk) of
primary tumor and those that do (i.e. high risk). Table 2
divides all entities listed in WHO classification scheme into
low risk and high risk categories. Histologic grading will
additionally split certain tumor types (i.e. mucoepidermoid
carcinoma) between both risk categories.
Is grading of salivary gland tumors always necessary?
The answer is no. Many tumor types are for the most part
definitionally high risk both histologically and biologically
(i.e. conventional salivary duct carcinoma, squamous cell
carcinoma, small cell neuroendocrine carcinoma) or low
risk (i.e. epithelial-myoepithelial carcinoma, polymorphous
low grade adenocarcinoma). The caveat is that high grade
versions of ‘intrinsically’ low grade tumors do exist as do
low grade versions of typically high grade tumors. Both
pathologists and clinicians need to be aware of these
variants. Thus:
• The usual example of such a tumor type may not need
to be qualified with a grading descriptor.
• An unusually high or low grade variant of a tumor
should be conveyed in the pathologic report.
Perhaps the most relevant example of this phenomenon
is with carcinoma ex pleomorphic adenoma. Historically
and even currently in the clinical literature, [2–4] carci-
noma ex pleomorphic adenoma is automatically considered
a high grade malignancy. In most cases, this is true with
high grade adenocarcinoma, not otherwise specified
(NOS), and salivary duct carcinoma being the most com-
mon histologic subtype of the carcinomatous component.
However, as many as 15% of tumors are low grade and
may behave in a more indolent fashion [5]. More recently,
there is evidence to suggest that ‘intracapsular’ carcinoma
ex pleomorphic adenoma and minimally invasive carci-
noma (\1.5 mm of invasion) ex pleomorphic adenoma
(Fig. 1) are also indolent variants that should not be con-
sidered equivalent to the typical carcinoma ex pleomorphic
adenoma.
Table 1 General categories of management of primary salivary gland carcinomas [3]
Surgery alone Surgery and radiotherapy Additional neck dissection Systemic chemotherapy
Negative margins Close (\2 mm) or positive margins All cN? Metastatic or unresectable
diseasecN0 but high grade histology
Low grade histology High grade histology cN0 but high risk (angioinvasive)
histologic subtype
Low risk (non angioinvasive,
non infiltrative) histologic
subtype
High risk (highly infiltrative)
histologic subtype
cN0 but high T stage (T3 or T4)
Low T stage (T1 or T2) High T stage (T3 or T4)
pN?
Perineural invasiona
T = tumor stage in TNM classification, cN? = clinically node positive, cN0 = clinically node negative, pN? = pathologically node positive
a Somewhat controversial depending on tumor type
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Thus ‘carcinoma ex pleomorphic adenoma’ in current
practice is not sufficient as a stand alone diagnosis. Rec-
ommendations for reporting on these tumors are:
• Histologic type/grade
• Percentage of carcinoma
• Extend of invasion of the carcinomatous component
(intracapsular, minimally invasive, and invasive).
For more common malignancies however, grading sys-
tems have evolved and applied with some degree of
efficacy. The two major named tumor types that are
consistently graded in current practice are adenoid cystic
carcinoma, and mucoepidermoid carcinoma. Additionally,
adenocarcinoma NOS and cystadenocarcinoma, are also
typically assigned a grade, though these tumors are not
common enough to generate a formal system. Finally,
grading of acinic cell carcinomas is somewhat controver-
sial. Typically considered a ‘low risk’ tumor, many studies
suggest an unusually high rate of lymph node metastasis as
compared to other low risk tumors. Additionally histologic
studies actually point to the ability to stratify these tumors
based on cytomorphologic grading parameters [6, 7] sug-
gesting that a grading system is necessary for these tumors.
Adenoid Cystic Carcinoma
Adenoid cystic carcinoma is a biphasic (composed of ducts
and basal/myoepithelial cells) salivary gland malignancy
characterized by tubular cribriform and or solid growth
patterns. The biologic course of this tumor overall is slow
but relentless—5 year survival is favorable at roughly
75–80%, but 15 year survival is poor at about 35% [8, 9].
Adenoid cystic carcinoma is unusual in that it is cytolog-
ically fairly monomorphic, yet locally quite aggressive
placing it in a ‘high risk’ category with regard to the use of
adjuvant radiation. In contrast, the likelihood of lymph
node involvement may be as low as 5%, and many insti-
tutions consider this tumor ‘low risk’ for lymph node
metastases and thus do not perform neck dissection if
clinicoradiographically node negative [3].
Grading of adenoid cystic carcinoma has been shown to
be prognostically useful in several series [9–11]. Unlike
Table 2 Risk stratification of WHO [1] recognized salivary gland malignancies
Low risk High Risk
Acinic cell carcinoma Sebaceous carcinoma and lymphadenocarcinoma
Low grade mucoepidermoid carcinomaa High grade mucoepidermoid carcinomaa
Epithelial-myoepithelial carcinoma Adenoid cystic carcinomab
Polymorphous low grade adenocarcinoma Mucinous adenocarcinoma
Clear cell carcinoma Squamous cell carcinoma
Basal cell adenocarcinoma Small cell carcinoma
Low grade salivary duct carcinoma (low grade cribriform cystadenocarcinoma) Large cell carcinoma
Myoepithelial carcinoma Lymphoepithelial carcinoma
Oncocytic carcinoma Metastasizing pleomorphic adenoma
Carcinoma ex pleomorphic adenoma (intracapsular/minimally invasive or with
low grade histology)
Carcinoma ex pleomorphic adenoma (widely invasive or high
grade histology)
Sialoblastoma Carcinosarcoma
Adenocarcinoma NOS and Cystadenocarcinoma, low gradea Adenocarcinoma and cystadenocarcinoma, NOS, high gradea
a Intermediate grade variants of these tumors are controversial in the assignment of risk. For mucoepidermoid carcinoma this may depend on
grading scheme used. For adenocarcinoma NOS, there is little data, but what is present suggests that intermediate grade should be placed in the
high risk group
b Adenoid cystic carcinomas are all considered high risk in terms of local recurrence, but only solid adenoid cystic carcinoma (i.e. high pattern
grade) is considered high risk for nodal metastasis
Fig. 1 Minimally invasive carcinoma ex pleomorphic adenoma. The
pleomorphic adenoma component with sclerosis is seen on the right,
and the minor low grade carcinoma component infiltrates the
surrounding adipose tissue. This carcinoma was immunophenotypi-
cally a myoepithelial carcinoma (stains not shown)
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many grading schemes, adenoid cystic carcinoma grading
quick and simple in that it is based solely on growth pat-
tern. As early as 1958, Patey and Thackray [12] noted that
a solid growth pattern imparts a poor prognosis. Subse-
quently, grading of this tumor has evolved into
stratification into three grades of increasing aggressiveness
based on predominant growth pattern: [10, 11] grade 1:
tubular, grade 2: cribriform, grade 3: solid (Fig. 2). Gen-
erally, a tumor with a greater than 30% solid component
belongs in the ‘grade 3’ category. However, it is suggested
that any solid component imparts a poor prognosis, and that
the relationship between solid growth pattern percentage
and prognosis is somewhat linear and that assigning a cut-
off may be arbitrary. The current WHO classification refers
to tumors by predominant pattern rather than actually
assigning a numeric grade.
One of the controversies surrounding grading of adenoid
cystic carcinoma is its prognostic utility independent of
tumor stage. Spiro et al. [8] suggest that this is not the case,
however, more recently, da Cruz Perez et al. [13] show that
grade is an independent prognosticator on multivariate
analysis. One potential difference that the grading scheme
used by Spiro et al. [8] differs from the typical scheme
particularly with regards to a solid component cut-off of
over [ 50%. The difficulties in conversion between the
two grading schemes are illustrated in Table 3. Repro-
ducibility of grading in adenoid cystic carcinoma has not
been well addressed in the literature. In one study, [14]
ironically, the grading system used by Spiro et al. [8] has
less interobserver variability.
While prognostically useful, it is unclear whether
grading of adenoid cystic carcinoma is useful in patient
management. Regardless of grade, all adenoid cystic
carcinomas are treated with surgery plus irradiation
because locally they are aggressive and ‘high risk’. With
regard to the neck, most decisions on the neck dissection
will not depend on grade, though there is some evidence
to suggest that solid/grade 3 adenoid cystic carcinomas
have a higher likelihood of lymph node metastasis [3].
With regards to this point, the rare phenomenon of
dedifferentiation or high grade transformation may have
relevance. Adenoid cystic carcinoma with high grade
transformation refers to the presence of a pleomorphic
mitotically active high grade carcinoma component aris-
ing in an otherwise conventional adenoid cystic
carcinoma of any pattern/grade (Fig. 3a) [15]. The trans-
formed component is typically of a purely ductal
phenotype with a solid or cribriform appearance. Unlike
conventional adenoid cystic carcinoma, which is charac-
terized by small, hyperchromatic, monomorphic nuclei,
and scant cytoplasm, transformed components show
prominent nuclear size and chromatin variability. Com-
mon features include fibrocellular desmoplasia, abundant
mitoses, necrosis, and microcalcifications. Unique patterns
in high grade transformation include micropapillary and
squamoid growth. However, there is still morphologic
overlap between solid conventional adenoid cystic carci-
noma and high grade transformation and the transition
from conventional adenoid cystic to high grade transfor-
mation is often gradual. Table 4 delineates key
distinguishing features between solid conventional ade-
noid cystic carcinoma and adenoid cystic carcinoma with
high grade transformation. Basically, the aggressive
nuclear, stromal, architectural and immunohistochemical
features common to both variants are more exaggerated in
high grade transformation, while solid conventional ade-
noid cystic carcinoma shows only slight deviation from
tubular or cribriform conventional adenoid cystic
carcinoma.
Fig. 2 The various patterns/
grades of adenoid cystic
carcinoma. a Tubular,
b cribriform, c solid. All grades
are cytologically monomorphic
and retain small dark angulated
nuclear features
Table 3 Comparison of common pattern grading schemes in adenoid
cystic carcinoma
Grade Perzin et al. [10],
Szanto et al. [11]
Grade Spiro et al. [8]
1 Predominantly tubular, no
solid component







3 Solid component [30% 2 50% solid
3 Mostly solid
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These tumors have an exceptionally poor prognosis with
a median survival ranging from 12 to 36 months, and may
thus be even more aggressive that solid or ‘grade 3’ ade-
noid cystic carcinoma. Unlike conventional adenoid cystic
carcinoma, this tumor has a lymph node metastatic rate of
over 50% (Fig. 3b). Thus if a transformed component is
found in an adenoid cystic carcinoma, a neck dissection is
likely warranted.
Summary recommendations for grading of adenoid
cystic carcinoma:
• Report predominant growth pattern (tubular, cribriform,
or solid)
• If any solid component is present give rough estimate
of percentage
Fig. 3 Adenoid cystic
carcinoma with high grade
transformation.
a A conventional cribriform
component with monomorphic
nuclei on top transitions to a
pleomorphic highly atypical
adenocarcinoma on bottom.
b The transformed component
metastasized to a cervical lymph
node
Table 4 Comparison of solid conventional adenoid cystic carcinoma and high grade transformationa
Features Solid conventional adenoid cystic carcinoma Adenoid cystic carcinoma with high grade transformation
Chromatin Dark, homogeneous Vesicular or heterogeneously dispersed
Nuclear membranes Delicate Thickened or irregular
Nucleoli Present but indistinct Prominent central
Nuclear size At most twice the size of grade I-II ACC
nuclei. Uniform size distribution
At least 2–3 times the size of grade I-II ACC nuclei
(typically more). At least 2 fold nuclear variation
Cytoplasm Scant to nearly absent Scant to moderate
Growth Solid nests, rarely spanning more than a
403 high power field
Solid confluent nests to sheets often filling a 403 high
power field
Stroma Paucicellular myxoid or hyaline Fibrocellular desmoplastic
Comedonecrosis Focally present, usually punctuate Often present, punctuate to large zones
Microcalcifications Rarely present Often present
Unique features Micropapillae, squamoid areas
Mitoses Generally \10/hpf Usually [10/hpf
Abluminal cell layer presence
by immunohistochemistry
Present and complete Incomplete and at least focally absent
Ki-67 \50% [50%
p53 overexpression (strong
reactivity in >50% of cells)
Rare Common
Bold = Major Features
a Adapted from Seethala et al. [15]
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• It may be reasonable to indicate in a comment that a
solid component [30% correlates with aggressive
behavior.
• If evidence of high grade transformation is present, this
should be reported and quantitated.
• A comment regarding the unusually high propensity
for lymph node involvement is recommended.
Mucoepidermoid Carcinoma
Mucoepidermoid carcinoma is the most common salivary
gland malignancy and is histologically comprised of a
mixture of mucus cells, intermediate cells and squamoid or
epidermoid cells. This tumor may also demonstrate clear
cell, oncocytic or columnar cells. There is arguably no
other salivary gland tumor in which grading is as important
to prognosis and therapy. The reported overall 5 year sur-
vival for MEC ranges from 92 to 100% for low grade
tumors, 62–92% for intermediate grade tumors, and 0–43%
for high grade tumors [16]. A few recent studies have also
highlighted the value of grade in the management of
patients [17, 18]. Low grade tumors generally require only
surgical treatment, while high grade tumors require adju-
vant radiation and neck dissection. The controversy arises
in the management of intermediate grade mucoepidermoid
carcinoma, and perhaps the root of this controversy lies
within the grading system employed.
Even when described initially by Stewart et al. [19] in
1945, two types of mucoepidermoid carcinoma were doc-
umented, a ‘benign’ and ‘malignant’ version which equate
today to low and high grade respectively. Shortly thereaf-
ter, the potential need for an intermediate category was
recognized [20]. Today, mucoepidermoid are carcinoma
graded by most using three tiers: low, intermediate and
high grade. The three most popular grading systems are:
the AFIP grading system [21], modified Healey sys-
tem [22], and the Brandwein [23] system (Table 5). All
categories assess a similar set of parameters, both
Table 5 Comparison of Grading Systems for Mucoepidermoid Carcinoma
Modified Healey [22] AFIP [21] Brandwein [23]
Qualitative Point based Point based




Macrocysts, microcysts, transition with excretory ducts Neural invasion
present = 2pts
Tumor invades in small nests
and islands = 2pts
Differentiated Mucin producing Epidermoid Cells, often in a 1:1





Daughter cyst proliferation from large cysts
Minimal to absent pleomorphism, rare mitoses
Broad-front, often circumscribed invasion
Pools of extravasated mucin with stromal reaction
Intermediate grade Mitosis (4 or more per
10 HPF) = 3pts
Lymphatic and/or vascular
invasion = 3pts
No macrocysts, few microcysts, solid nests of cells Anaplasia = 4pts Bony invasion = 3pts
Large duct not conspicuous [4mitoses per 10 HPF = 3pts
Slight to moderate pleomorphism, few mitoses, prominent nuclei and nucleoli
Invasive quality, usually well difined and uncircumscribed
Chronic inflammation at periphery, fibrosis separates nests of cells and
groups of nests
High grade Perineural spread = 3pts
No macrocysts, predominantly solid but may be nearly all glandular Necrosis = 3pts
Cell constituents range from poorly differentiated to recognizable epidermoid and
intermediate to ductal type adenocarcinoma
Considerable pleomorphism, easily found mitoses
Unquestionable soft tissue, perineural and intravascular invasion
Chronic inflammation less prominent, desmoplasia of stroma may outline invasive
clusters
Low grade = 0–4 pts Low grade = 0 pts
Intermediate
grade = 5–6 pts
Intermediate grade = 2–3 pts
High grade = 7–14 pts High grade = 4 or more pts
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cytomorphologic and architectural, and may also include
perineural and angiolymphatic invasion. Both the AFIP and
Brandwein system are point based, assigning point values
to each adverse histologic parameters and with ascending
point scores equating to a higher grade. The modified
Healey system can be considered a ‘best fit’ type system:
certain histologic parameters characterize a particular
grade, and a tumor is graded based on its predominant
morphologic features.
Grading of mucoepidermoid carcinoma is not without
flaws. One clear deficiency in all systems, particularly the
point based schemes, the difficulty in application. Grad-
ing under these systems is a cumbersome and time
consuming activity, and many of the criteria are not at all
well-defined. In fact, based on personal experience, if
asked, most pathologists tend not to use a formal system
because of the time commitment and lack of ‘user
friendliness.’ However, evidence suggests that the repro-
ducibility of an informal or personal grading scheme is
lower than when a standard grading scheme is used
[23, 24] (Fig. 4).
Given an adequate sample size, all systems appear to be
prognostically useful even independent of stage. However,
the way in which each system correlates with outcome
varies. The AFIP system appears to ‘down grade’ tumors
while the Brandwein system appears to ‘upgrade’ tumors
[24]. While these differences appear minor prognostically,
therapeutically they have significant implications. The
clinical expectation of a low grade mucoepidermoid car-
cinoma is that it is a ‘low risk’ tumor that is almost always
cured by surgery alone and has a negligible lymph node
metastatic rate. Here the danger of the AFIP system is
potentially placing biologically more aggressive tumors
into this low grade category increasing the failure rate of
low grade tumors. Conversely, high grade mucoepidermoid
carcinomas are aggressive tumors requiring adjuvant
treatment and neck dissection. The concern with the
Brandwein system is that it may place some indolent
tumors in this high risk category, in which case some
patients may receive unnecessary radiation or additional
surgery.
The differences in grading schemes are amplified par-
ticularly with respect to intermediate grade tumors. There
does not appear to be a clear cut answer on the manage-
ment of patients in this category, but the few studies
addressing this question on a single institution yield vary-
ing results. Aro et al. [17] using the AFIP system suggest
that intermediate grade mucoepidermoid carcinoma cluster
with high grade mucoepidermoid carcinoma, and should be
treated in a similar fashion. However, Nance et al. [18]
showed that intermediate grade mucoepidermoid carci-
noma cluster with low grade mucoepidermoid carcinoma
using the Brandwein system. Based on limited experience,
the Healey system does not seem to have either of these
limitations, but since intermediate grade tumors using this
system literally behave in a fashion that is ‘intermediate’ to
low and high grade, management may be even more
ambiguous than with the other systems.
Finally, variants of mucoepidermoid carcinoma such as
oncocytic or sclerosing variants may not be amenable to
conventional grading schemes. Limited evidence to date
suggests that even oncocytic mucoepidermoid carcinomas
that are considered high grade (Fig. 5) by a conventional
grading scheme may behave indolently, with only one
recurrence noted [25]. However, evidence is still insuffi-
cient to make a firm recommendation to discard grading for
these variants.
Thus current recommendations for grading mucoepi-
dermoid carcinomas are:
• Utilize a standard scheme, rather than an ‘intuitive’
approach. (As a more streamlined well defined system
Fig. 4 Grading of mucoepidermoid carcinoma. a A low grade tumor
demonstrating a well demarcated border, macrocystic spaces and a
bland cyst lining. b An intermediate grade tumor demonstrating a
more solid growth with only few microcysts, and focal infiltration. It
is important to note that the Brandwein system may potentially
classify this tumor as high grade (infiltration if these nests are
considered ‘small enough’, and intracystic component\25% equates
to 4 points), while the AFIP grading system still categorizes this
tumor as low grade (score is only 2/14). c High grade mucoepider-
moid carcinoma with no cystic spaces and a highly infiltrative growth
pattern. Inset: showing anaplasia or pronounced nuclear atypia
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evolves that still retains predictive value, this notion
may become more palatable).
• Regarding which system to use, understanding of the
clinical expectations is necessary. In most practices in
the United States, it is less acceptable for a low grade
tumor to behave in an aggressive fashion than for a high
grade tumor to behave indolently and possibly get
overtreatment. Thus, the utilization of the Brandwein
system or Healey system is preferable.
• Variants should still be graded in a similar fashion
although limited evidence suggests that some variants may
behave more indolently even if technically high grade.
Conclusions
Though histologic grading of salivary gland carcinomas is
somewhat flawed, it does have prognostic value. Carci-
noma ex pleomorphic adenoma should no longer be
considered a specific diagnosis, but rather, a category in
which the carcinoma should be typed, graded and quanti-
tated to impart more prognostically and therapeutically
relevant data. The two tumor types for which specific
grading systems have evolved are adenoid cystic carci-
noma and mucoepidermoid carcinoma. Adenoid cystic
carcinoma is graded based on growth pattern with solid
growth imparting a poorer prognosis. Rarely, these tumors
will undergo high grade transformation in which case the
tumor will have a much higher predilection for lymph node
metastases than a conventional adenoid cystic carcinoma.
In mucoepidermoid carcinomas, standardized grading
systems are more reproducible than generic grade assign-
ment, but in their current form, they are cumbersome and
time consuming. The outcome in the intermediate grade
category is heavily dependent on the grading system used
and is thus the most controversial with regards to man-
agement and prognosis. The AFIP system downgrades
tumors leading to aggressive behavior in the intermediate
grade category while the Brandwein system upgrades
tumors resulting in indolent behavior.
References
1. Eveson JW, Auclair PL, Gnepp DR, et al. Tumors of the salivary
glands: introduction. In: Barnes EL, Eveson JW, Reichart P, Si-
dransky D, editors. World Health Organization classification of
tumours: pathology & genetics. Head and neck tumours. Lyon:
IARCPress; 2005. p. 221–2.
2. Bell RB, Dierks EJ, Homer L, et al. Management and outcome of
patients with malignant salivary gland tumors. J Oral Maxillofac
Surg. 2005;63(7):917–28.
3. Myers EN, Ferris RL, editors. Salivary gland disorders. Berlin:
Springer; 2007.
4. Lima RA, Tavares MR, Dias FL, et al. Clinical prognostic factors
in malignant parotid gland tumors. Otolaryngol Head Neck Surg.
2005;133(5):702–8.
5. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic ade-
noma: pathologic analysis of 73 cases. Hum Pathol. 2001;32(6):
596–604.
6. Lewis JE, Olsen KD, Weiland LH. Acinic cell carcinoma. Clin-
icopathologic review. Cancer. 1991;67(1):172–9.
Fig. 5 Oncocytic
mucoepidermoid carcinoma. a
This solid highly infiltrative
oncocytic lesion would be
classified in some grading
schemes as high grade. b The
tumor cells have abundant
granular eosinophilic
cytoplasm. c Only rare foci with
mucus cells are noted. This
patient suffered one recurrence
8 years after diagnosis but is
currently free of disease for
almost 5 years
76 Head and Neck Pathol (2009) 3:69–77
7. Michal M, Skalova A, Simpson RH, et al. Well-differentiated
acinic cell carcinoma of salivary glands associated with lymphoid
stroma. Hum Pathol. 1997;28(5):595–600.
8. Spiro RH, Huvos AG. Stage means more than grade in adenoid
cystic carcinoma. Am J Surg. 1992;164(6):623–8.
9. Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carci-
noma of the head and neck: predictors of morbidity and mortality.
Arch Otolaryngol Head Neck Surg. 1999;125(2):149–52.
10. Perzin KH, Gullane P, Clairmont AC. Adenoid cystic carcinomas
arising in salivary glands: a correlation of histologic features and
clinical course. Cancer. 1978;42(1):265–82.
11. Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of
adenoid cystic carcinoma of the salivary glands. Cancer.
1984;54(6):1062–9.
12. Patey DH, Thackray AC. The treatment of parotid tumours in the
light of a pathological study of parotidectomy material. Br J Surg.
1958;45(193):477–87.
13. da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, et al.
Prognostic factors in head and neck adenoid cystic carcinoma.
Oral Oncol. 2006;64(11):1592–97.
14. Therkildsen MH, Reibel J, Schiodt T. Observer variability in
histological malignancy grading of adenoid cystic carcinomas.
APMIS. 1997;105(7):559–65.
15. Seethala RR, Hunt JL, Baloch ZW, et al. Adenoid cystic carci-
noma with high-grade transformation: a report of 11 cases and a
review of the literature. Am J Surg Pathol. 2007;31(11):1683–94.
16. Ellis G, Auclair P, editors. Tumors of the salivary glands. Atlas of
tumor pathology. No. 17, 3rd Series ed. Washington DC: Armed
Forces Institute of Pathology; 1996.
17. Aro K, Leivo I, Makitie AA. Management and outcome of
patients with mucoepidermoid carcinoma of major salivary gland
origin: a single institution’s 30-year experience. Laryngoscope.
2008;118(2):258–62.
18. Nance MA, Seethala RR, Wang Y, et al. Treatment and survival
outcomes based on histologic grading in patients with head and
neck mucoepidermoid carcinoma. Cancer. 2008;113(8):2082–9.
19. Stewart FW, Foote FW, Becker WF. Mucoepidermoid tumors of
salivary glands. Ann Surg. 1945;122:820–44.
20. Foote FW Jr, Frazell EL. Tumors of the major salivary glands.
Cancer. 1953;6(6):1065–133.
21. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of
the major salivary glands: clinical and histopathologic analysis of
234 cases with evaluation of grading criteria. Cancer. 1998;
82(7):1217–24.
22. Batsakis JG, Luna MA. Histopathologic grading of salivary gland
neoplasms: I mucoepidermoid carcinomas. Ann Otol Rhinol
Laryngol. 1990;99(10 Pt 1):835–8.
23. Brandwein MS, Ferlito A, Bradley PJ, et al. Diagnosis and classi-
fication of salivary neoplasms: pathologic challenges and relevance
to clinical outcomes. Acta Otolaryngol. 2002; 122(7):758–64.
24. Seethala RR, Hoschar AP, Bennett A, et al. Reproducibility of
grading in salivary gland mucoepidermoid carcinoma and cor-
relation with outcome: does system really matter? Mod Pathol.
2008;21(S1):241A.
25. Weinreb I, Seethala RR, Perez-Ordonez B, et al. Oncocytic
mucoepidermoid carcinoma: clinicopathologic description in a
series of 12 cases. Am J Surg Pathol. Oct 28 2008 [Epub ahead of
print].
Head and Neck Pathol (2009) 3:69–77 77
